TORNA ALL’ELENCO

Second primary malignancy in myelofibrosis patients treated with ruxolitinib in Haematologica

2019
AOU Città della Salute di Torino

Tipo pubblicazione

Conference Abstract

Autori/Collaboratori (37)Vedi tutti...

Polverelli N

Elli E

Abruzzese E


et alii...

Abstract

Ruxolitinib (RUX), the first JAK1/JAK2 inhibitor approved for myelofibrosis (MF) therapy, has been recently associated with the occurrence of second primary malignancies (SPMs), mainly lymphoid neoplasms and non-melanoma skin cancers (NMSCs). Herein, we analyzed incidence and risk factors of SPMs in 589 MF pts treated with RUX in 20 European Hematology Centers. Cumulative incidence of SPMs was calculated according to Fine and Gray model with death without SPM as competitive event. Uni and multivariate analysis were carried out by Fine-Gray proportion hazard regression for competing risks. The characteristics of the MF cohort were the following: median age 65y (15-88); male gender 58%; PMF 51%; JAK2, CALR and MPL mutation 83%, 11% and 2% of 530 evaluable pts; median RUX exposure 36 mos (1-86), prior cytoreduction use in 362 pts (HU 98%), previous neoplasms in 40 pts (43 events). Seventy pts (12%) developed 74 SPMs after RUX start, with a cumulative incidence of 2.3%, 4.5% and 14.3% at 1, 2 and 5y, respectively. Incidence rate of SPMs was 3.91 100 pts/y. Clinical features were comparable between pts with or without SPMs. NMSCs were the most common SPMs accounting for 38 events in 34 pts, other neoplasms involved urological district (13), lung (9), GI tract (6), hematopoietic tissue (2, 1 CML and 1 Langherhans cell histiocytosis), others (6). In 17 out of 213 deceased pts (8%), SPM was the ultimate cause of death. SPM diagnosis did not affect OS, even after excluding NMSC, with projected survival of 81 and 84% at 2y for pts with or without SPM (p=0.96). By univariate analysis, age at RUX start >55y (p=0.035), CALR mutation (p=0.023), HU time-exposure (p=0.003) and male sex (p<0.001) were associated with increased incidence of SPMs; in multivariate analysis, CALR mutation, HU use and sex maintained statistical significance (HR 3.78, CI95% 1.61-8.87 p=0.002, HR 1.07, CI95% 1.02-1.13 p=0.01 and HR 2.63, CI95% 1.08-6.43, p=0.034 respectively). After exclusion of NMS

DOI : 10.3324/haematol.2018.205989

Keywords

endogenous compound; Janus kinase 2; Janus kinase 2 inhibitor; ruxolitinib; adverse drug reaction; aged; cancer patient; cancer prognosis; cancer survival; cause of death; clinical feature; cohort analysis; conference abstract; controlled study; drug therapy; female; gastrointestinal tract; gender; genetic susceptibility; hematology; hematopoietic tissue; histiocytosis; human; incidence; lung; lymphatic system tumor; major clinical study; male; myelofibrosis; non melanoma skin cancer; risk assessment; risk factor; second cancer; side effect; statistical significance; univariate analysis;